Inflammatory bowel disease, or IBD in short, refers to a group of disorders characterized by chronic inflammation of the gastrointestinal tract. IBD primarily includes Crohn's disease and ulcerative colitis. It is estimated that 2.4 million individuals are currently diagnosed with IBD in the U.S., with 70,000 new cases being diagnosed each year.
The company we are profiling today is Spyre Therapeutics Inc. (SYRE), a clinical-stage biotechnology company developing next generation therapeutics for people living with IBD, including ulcerative colitis and Crohn's disease.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com